Renal protection with glucagon-like peptide type 1 receptor agonists In CVOTs of arGLP1 renal outcomes were prespecified as key secondary outcomes in 4 studies done with liraglutide, subcutaneous semaglutide, dulaglutide, and efpeglenatide,58,59,63,64 or were collected as safety parameters in other studies.60 Overall, the prevalence of CKD stage 3 in these studies was low (2030%) (Table 1)
ISSN 1938-3207
In contrast, certain other GLP-1 receptor agonists (liraglutide, semaglutide, dulaglutide) have demonstrated cardiovascular benefits in their respective outcomes trials
DSIP plays a role in regulating the endocrine system, which is responsible for hormone production and balance
Does IV Therapy Work
The Royal Society of Chemistry 3, pp